Ernst Lengyel

c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion.

Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy.

Role of beta(3)-endonexin in the regulation of NF-kappaB-dependent expression of urokinase-type plasminogen activator receptor.

Tumor-specific transcription factor binding to an activator protein-2/Sp1 element of the urokinase-type plasminogen activator receptor promoter in a first large series of resected gastrointestinal cancers.

Single-agent pulse dactinomycin has only modest activity for methotrexate-resistant gestational trophoblastic neoplasia.

C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu.

Isolation and characterization of Rac1 pseudogenes (psi1Rac1-psi4Rac1) in the human genome.

Rac1b, a tumor associated, constitutively active Rac1 splice variant, promotes cellular transformation.

Combination analysis of activator protein-1 family members, Sp1 and an activator protein-2alpha-related factor binding to different regions of the urokinase receptor gene in resected colorectal cancers.

Tyrosine kinase mutations in human cancer.

Src induces urokinase receptor gene expression and invasion/intravasation via activator protein-1/p-c-Jun in colorectal cancer.

Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extra-cellular matrices on adhesion and invasion of ovarian cancer cells to the omentum.

Let-7 expression defines two differentiation stages of cancer.

Let-7 prevents early cancer progression by suppressing expression of the embryonic gene HMGA2.

Thrombin induces tumor invasion through the induction and association of matrix metalloproteinase-9 and beta1-integrin on the cell surface.

The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin.

Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target.

The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2.

A novel multipurpose monoclonal antibody for evaluating human c-Met expression in preclinical and clinical settings.

Does equal treatment yield equal outcomes? The impact of race on survival in epithelial ovarian cancer.

A special key for unlocking the door to targeted therapies of breast cancer.

MMP-2 functions as an early response protein in ovarian cancer metastasis.

Up-regulation of alpha5-integrin by E-cadherin loss in hypoxia and its key role in the migration of extravillous trophoblast cells during early implantation.

Rac1 and Rho contribute to the migratory and invasive phenotype associated with somatic E-cadherin mutation.

The molecular signature of endometriosis-associated endometrioid ovarian cancer differs significantly from endometriosis-independent endometrioid ovarian cancer.

Effects of oral contraceptives or a gonadotropin-releasing hormone agonist on ovarian carcinogenesis in genetically engineered mice.

Organotypic models of metastasis: A three-dimensional culture mimicking the human peritoneum and omentum for the study of the early steps of ovarian cancer metastasis.

{beta}3-integrin expression on tumor cells inhibits tumor progression, reduces metastasis, and is associated with a favorable prognosis in patients with ovarian cancer.

The Müllerian HOXA10 gene promotes growth of ovarian surface epithelial cells by stimulating epithelial-stromal interactions.

An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis.

CD95 promotes tumour growth.

Ovarian cancer development and metastasis.

Targeting the urokinase plasminogen activator receptor inhibits ovarian cancer metastasis.

The expression of hepatocyte growth factor (HGF) and c-Met in uterine serous carcinoma.

A phase II, single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer.

Acute inflammatory reaction following placement of sodium hyaluronate-carboxymethylcellulose barrier in a young woman undergoing gynecologic surgery: a case report.

Foretinib (GSK1363089), an orally available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis.

Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1.

FOXL2 and SOX9 distinguish the lineage of the sex cord-stromal cells in gonadoblastomas.

Rethinking ovarian cancer: recommendations for improving outcomes.

The effects of 17β-estradiol and a selective estrogen receptor modulator, bazedoxifene, on ovarian carcinogenesis.

The first line of intra-abdominal metastatic attack: breaching the mesothelial cell layer.

Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth.

Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity.

Clinico-pathologic comparison of type II endometrial cancers based on tamoxifen exposure.

HOXA9 promotes ovarian cancer growth by stimulating cancer-associated fibroblasts.

MicroRNAs reprogram normal fibroblasts into cancer-associated fibroblasts in ovarian cancer.

Serial sectioning of the fallopian tube allows for improved identification of primary fallopian tube carcinoma.

miR-92a inhibits peritoneal dissemination of ovarian cancer cells by inhibiting integrin α5 expression.

Adipose tissue and adipocytes support tumorigenesis and metastasis.

Summary of the 2013 American Association for Cancer Research (AACR) Annual Meeting.

Urokinase plasminogen activator system-targeted delivery of nanobins as a novel ovarian cancer therapy.

Expression of the homeobox gene HOXA9 in ovarian cancer induces peritoneal macrophages to acquire an M2 tumor-promoting phenotype.

Three-dimensional modeling of ovarian cancer.

Statin therapy is associated with improved survival in patients with non-serous-papillary epithelial ovarian cancer: a retrospective cohort analysis.

Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion.

Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models.

Old drug, new trick: repurposing metformin for gynecologic cancers?

Quantitative high throughput screening using a primary human three-dimensional organotypic culture predicts in vivo efficacy.

Molecular pathways: trafficking of metabolic resources in the tumor microenvironment.

Patterns and utility of routine surveillance in high grade endometrial cancer.

The hypoxia-related microRNA miR-199a-3p displays tumor suppressor functions in ovarian carcinoma.

Whole-genome characterization of chemoresistant ovarian cancer.

Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma.

Hyperglycemia-induced metabolic compensation inhibits metformin sensitivity in ovarian cancer.

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer.

Corrigendum: Whole-genome characterization of chemoresistant ovarian cancer.